Preoperative staging in patients with pancreatic cancer
Miroslav Ryska1
+ Affiliation
Summary
Radical resection with adjuvant chemotherapy is only potential curable therapeutic modality enabling to prolong survival of 20 % patients. Borderline conception contents active approach to primary non-resectable patients to reach resectability by neoadjuvant chemo (radio) therapy. Preoperative staging is main condition of effective therapeutic approach.
Keywords
diagnosis, pancreatic carcinoma, quality of life, therapyTo read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. SVOD. Český národní webový portál epidemiologie nádorů. [online]. Dostupné z: www.svod.cz/.
2. Carrato A, Falcone A, Ducreux M et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. J Gastrointest Canc 2015; 46 (3): 201–211. doi: 10.1007/s12029-015-9724-1.
3. Cooper M, Newman NA, Ibrahim AM et al. Unnecessary tests and procedures in patients presenting with solid tumors of the pankreas. J Gastrointest Surg 2013; 17 (7): 1218–1223. doi: 10.1007/s11605-013-2213-6.
4. Ryska M, Dušek L, Pohnán R et al. Kvalita života je důležitým faktorem indikační rozvahy u nemocných s karcinomem pankreatu. Multicentrická prospektivní studie. Rozhl Chir 2012; 91: 207–216.
5. Pietryga JA, Morgan DE. Imaging pre- operatively for pancreatic adenocarcinoma. J Gastrointest Oncol 2015; 6 (4): 343–357. doi: 10.3978/j.issn.2078-6891.2015.024.
6. Ardengh JC, Malheiros CA, Pereira V et al. Endoscopic ultrasound-guided fine-needle aspiration using helical computerized tomography for TN staging and vascular injury in operable pancreatic carcinoma. JOP 2009; 10 (3): 310–317.
7. Petr WT, Pistes MD, Wayne A et al: Effect of praeoperative biliary decompression on pancreaticoduodenectomy – associated morbidity in 300 consecutive patients. Ann Surg 2001; 234 (4): 47–55.
8. Ducreux M, Cuhna AS, Caramelia C et al. Cancer of the pankreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl 5): v56–v68. doi: 10.1093/annonc/mdv295.
9. Tempero, MA, Arnoletti JP, Behrman SW et al. Pancreatic adenocarcinoma, vision 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10 (6): 703–713.
10. Oettle H, Neuhaus P, Hochhaus A et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patiens with resected pancreatic cancer – the CONCO-001 randomized trial. JAMA 2013; 310 (14): 1473–1481. doi: 10.1001/jama.2013.279201.
11. Nimura Y, Nagino M, Takao S et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012; 19 (3): 230–241. doi: 10.1007/s00534-011-0466-6.
12. Büchler MW, Wagner M, MD, Schmied BM et al. Changes in morbidity after pancreatic resection. Toward the end of completion pancreatectomy. Arch Surg 2003; 138 (12): 1310–1314.
13. Katz MH, Marsh R, Herman JM et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013; 20 (8): 2787–2795. doi: 10.1245/ s10434-013-2886-9.
14. Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. WJG 2014; 20 (31): 10740–10751. doi: 10.3748/wjg.v20.i31.10740.
15. Katz MH, Fleming JB, Bhosale P et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012; 118 (23): 5749–5756. doi: 10.1002/cncr.27636.
16. Barugola G, Partelli S, Crippa S et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg 2012; 203 (2): 132–139. doi: 10.1016/j.amjsurg.2011.03.008.
17. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–2001 FfCD/SFRO study. Ann Oncol 2008; 19 (9): 1592–1599. doi: 10.1093/annonc/mdn281.
18. Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat ? Ther Adv Gastroenterol 2013; 6 (4): 321–337. doi: 10.1177/1756283X13478680.
19. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64 (1): 9–29. doi: 10.3322/caac.21208.
20. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467 (7319): 1114–1117. doi: 10.1038/nature09515.
21. Lowenfels AB, Maisonneuve P. Pancreatico-biliary malignancy: prevalence and risk factors. Ann Oncol 1999; 10 (Suppl 4): S1–S3.
22. Pawlik TM, Gleisner AL, Cameron JL et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007; 141 (5): 610–618.
23. Rochefort Mm, Ankeny JS, Kadera BE et al. Impact of tumor grade on pancreatic cancer prognosis: validation of a Novel TNMG Staging System. Ann Surg Oncol 2013; 20 (13): 4322–4329. doi: 10.1245/ s10434-013-3159-3.
24. Verbeke CS, Leitch D, Menon KV et al. Redefining the R1 resection in pancreatic cancer. Br J Surg 2006; 93: 1232–1237.
25. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the word. HPB 2008; 10 (1): 58–62. doi: 10.1080/13651820701883148.